HIGHLIGHTS
- who: Ryutaro Taenaka from the Department of Medicine and Biosystemic Sciences, Kyushu University Fukuoka, Japan have published the Article: Successful treatment with daratumumab, lenalidomide, and dexamethasone therapy followed by autologous stem cell transplantation for newly diagnosed polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes syndrome: a case report, in the Journal: (JOURNAL)
SUMMARY
Transplant-eligible patients with polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes (POEMS) syndrome are treated with induction therapy and autologous stem_cell transplantation (ASCT). Daratumumab, lenalidomide, and dexamethasone (DLd) therapy has been reported as a less neurotoxic, highly effective therapy for patients . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.